Plasma Epstein-Barr virus microRNA BART8-3p as a potential biomarker for detection and prognostic prediction in early nasopharyngeal carcinoma
- PMID: 38548853
- PMCID: PMC10978918
- DOI: 10.1038/s41598-024-58233-1
Plasma Epstein-Barr virus microRNA BART8-3p as a potential biomarker for detection and prognostic prediction in early nasopharyngeal carcinoma
Abstract
Epstein-Barr virus (EBV) encoded microRNA BART8-3p (miR-BART8-3p) was significantly associated with the metastasis in nasopharyngeal carcinoma (NPC). To explore the clinical values of plasma miR-BART8-3p in patients with early NPC. We retrospectively analyzed 126 patients with stage I and II NPC. A receiver operating characteristic curve was used to examine the diagnostic performance. Kaplan‒Meier analysis was applied to determine survival differences. Cox regression was used for univariate and multivariate analyses. Compared to healthy subjects, plasma EBV miR-BART8-3p was highly expressed in early NPC patients. The sensitivity, specificity, and area under the curve value of plasma miR-BART8-3p combined with plasma EBV DNA was up to 88.9%, 94.4%, and 0.931. Compared to patients with low expression of miR-BART8-3p, patients with high expression of miR-BART8-3p had poorer 5-year overall survival (OS) (98.9% vs. 91.1%, P = 0.025), locoregional recurrence-free survival (LRRFS) (100% vs. 83.9%, P < 0.001) and distant metastasis-free survival (DMFS) (98.9% vs. 88.0%, P = 0.006). Risk stratification analysis revealed that high-risk patients (with high levels of EBV DNA and miR-BART8-3p) had inferior OS, LRRFS, and DMFS than low-risk patients (without high levels of EBV DNA and miR-BART8-3p). Multivariate analysis verified that the high-risk group was an unfavorable factor for OS, LRRFS, and DMFS. A combination of plasma EBV miR-BART8-3p and EBV DNA could be a potential biomarker for the diagnosis and prognosis in early NPC.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10978918/bin/41598_2024_58233_Fig1_HTML.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10978918/bin/41598_2024_58233_Fig2_HTML.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10978918/bin/41598_2024_58233_Fig3_HTML.gif)
Similar articles
-
Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.Oncologist. 2022 Apr 5;27(4):e340-e349. doi: 10.1093/oncolo/oyac024. Oncologist. 2022. PMID: 35380720 Free PMC article.
-
Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.Cancer Sci. 2020 May;111(5):1711-1723. doi: 10.1111/cas.14381. Epub 2020 Apr 9. Cancer Sci. 2020. PMID: 32155300 Free PMC article.
-
EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways.J Exp Clin Cancer Res. 2018 Nov 26;37(1):283. doi: 10.1186/s13046-018-0953-6. J Exp Clin Cancer Res. 2018. PMID: 30477559 Free PMC article.
-
The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases.Medicine (Baltimore). 2015 May;94(20):e845. doi: 10.1097/MD.0000000000000845. Medicine (Baltimore). 2015. PMID: 25997061 Free PMC article. Review.
-
Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.Methods Mol Biol. 2020;2204:99-107. doi: 10.1007/978-1-0716-0904-0_9. Methods Mol Biol. 2020. PMID: 32710318 Review.
References
MeSH terms
Substances
Grants and funding
- 2020GGB010/Fujian Province Health Middle-aged and Young backbone personnel training Project
- 2020Y2012/National Clinical Key Specialty Construction Program and the Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy
- 82373200/National Natural Science Foundation of China
- 2023J011253/Fujian Provincial Natural Science Foundation of China
- 2022YNG15/High-level Talent Development Program
LinkOut - more resources
Full Text Sources
Medical